All In Biotech

Drug Trial Radar · NCT04424511

Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali

LAKANA , a Cluster-randomized, Double-blinded, Parallel Group, Controlled Trial, Testing the Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Rural Mali.

Last checked: Nov 19, 2026Latest source record: May 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 149,201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

149,201

Actual

Start

Oct 15, 2020

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
Tampere UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Center for Vaccine Development CVD-Mali, Bamako, Mali; University College London Hospitals; Tro Da Ltd, UK; Duke-NUS Graduate Medical School; Bill and Melinda Gates Foundation; Pfizer Inc. (Provider of study drugs)
First posted
Jun 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 29 days, up to 364 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The LAKANA trial will assess the impact on mortality and other health outcomes of quarterly and biannual azithromycin mass drug administration (MDA) when delivered to 1-11-month (29-364 days) old infants in a high-mortality setting where malaria is holoendemic but there is also a functioning seasonal malaria chemoprevention (SMC) program in place. The long-term goal is to more precisely define the role of mass azithromycin treatments as an intervention for reducing childhood mortality, and to determine the most effective treatment regimen. The main study hypotheses in terms of mortality effect are: i) Biannual azithromycin MDA to 1-11 month old infants reduces their mortality, ii) Quarterly azithromycin MDA to 1-11 month old infants reduces their mortality, iii) Quarterly azithromycin MDA has a bigger mortality effect than biannual MDA.

Conditions

  • Mortality

Interventions

  • PlaceboDrug

    Placebo mixture will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml / kg child weight.

  • AzithromycinDrug

    Azithromycin will be administered as a single dose in oral suspension form for children 1-11 months of age. Weight-based dosing will be used: single-dose of 0.5 ml (20 mg) / kg child weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MortalityTime frame: 3-month time interval (total of 8 intervals per cluster)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Center for Vaccine Development CVD-Mali

    Bamako, Mali

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.